Neither work in any appreciable way, in fact, both

Neither work in any appreciable way, in fact, both effectively shut down the immune system and allow for secondary infections (highly likely) as well as liver complication and malignancies.

https://www.covid19treatmentguidelines.nih.go...nhibitors/

Quote:

---

Recommendation
The Panel recommends against the use of anti-IL-6 receptor monoclonal antibodies (e.g., sarilumab, tocilizumab) or anti-IL-6 monoclonal antibody (siltuximab) for the treatment of COVID-19, except in a clinical trial (BI).
Rationale
Preliminary, unpublished data from randomized, controlled trials failed to demonstrate efficacy of sarilumab or tocilizumab in patients with COVID-19. There are only limited, unpublished data describing the efficacy of siltuximab in patients with COVID-19.11

---

The UK is taking a page from the US and just approving anything to try to keep the sheep calm. Disgusting.

Quote:

---

The UK government is working closely with the manufacturer, to ensure the drugs - tocilizumab and sarilumab - continue to be available to UK patients.

---